Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib

Mutalisk: a web-based somatic MUTation AnaLyIS toolKit for genomic, transcriptional and epigenomic signatures

(2018) Jongkeun Lee et al.   NUCLEIC ACIDS RESEARCH

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal

(2018) James X. Sun et al.   PLoS Computational Biology

Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors

(2017) Hani M. Babiker et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

BRCA1 gene: function and deficiency

(2017) Miho Takaoka et al.   International Journal of Clinical Oncology

Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma

(2017) Ling Zeng et al.   MOLECULAR CANCER THERAPEUTICS

BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors

(2017) Hana Paculová et al.   TUMOR BIOLOGY

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer

(2017) Ethan Brill et al.   Oncotarget

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

(2016) David Hong et al.   JOURNAL OF CLINICAL ONCOLOGY

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia

(2016) Andrea Ghelli Luserna Di Rorà et al.   Oncotarget

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics

(2016) Florian Engert et al.   Oncotarget

Osteosarcoma: Current Treatment and a Collaborative Pathway to Success

(2015) Michael S. Isakoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Establishment of a patient-derived orthotopic osteosarcoma mouse model

(2015) Claudia Blattmann et al.   Journal of Translational Medicine

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms

(2015) C. King et al.   MOLECULAR CANCER THERAPEUTICS

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

(2015) Michal Kovac et al.   Nature Communications

The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design

(2013) Ruth Thompson et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Osteosarcoma treatment – Where do we stand? A state of the art review

(2013) Anja Luetke et al.   CANCER TREATMENT REVIEWS

Checkpoint kinase 1 in DNA damage response and cell cycle regulation

(2013) Mallikarjun Patil et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy

(2013) S. McNeely et al.   PHARMACOLOGY & THERAPEUTICS

Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation

(2012) T. Popova et al.   CANCER RESEARCH

The Mre11 Nuclease Is Critical for the Sensitivity of Cells to Chk1 Inhibition

(2012) Ruth Thompson et al.   PLoS One

Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents

(2012) Nicolai J. Birkbak et al.   Cancer Discovery

Anticancer therapy with checkpoint inhibitors: what, where and when?

(2011) Michelle D. Garrett et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

DNA Damage Response Pathways in Tumor Suppression and Cancer Treatment

(2008) Yulong Liang et al.   WORLD JOURNAL OF SURGERY